Research for identifying aggravating factors and establishing effective interventions to prevent dementia progression

Research for identifying aggravating factors and establishing effective interventions to prevent dementia progression - aggravating factors and prevention in dementias

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052032

Enrollment

2000

Registered

2023-09-01

Start date

2023-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia (Alzheimer&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Retrospective study 1.Patients diagnosed with Alzheimer's disease(AD), dementia with Lewy bodies(DLB), frontotemporal lobar degeneration(FTLD), argyrophilic grain disease(AGD), or limbic predominant age-related TDP-43 encephalopathy(LATE) based on the following diagnostic criteria AD: Diagnostic criteria for AD from the National Institute of Aging and the Alzheimer Association(NIA-AA) DLB: Clinical diagnostic criteria for DLB by McKeith et al. (2017) FTLD: Diagnostic criteria for bvFTD by Rascovsky et al. (2011) and SD and PNFA by Gorno-Tempini et al. (2011) AGD: Guidelines for the Treatment of Dementia Diseases 2017, Japanese Society of Neurology LATE: Based on the report of Nelson et al. (2022) and imaging findings of hippocampal sclerosis on MRI 2.Patients with head MRI and VSRAD results using Voxel-based morphometry (VBM) 3.Patients who have consented to participate in previous dementia studies and opt out Prospective study 1.Outpatients or first-time patients diagnosed based on the same criteria as in 1 of the retrospective studies 2.Patients who have consented to participate in this study

Exclusion criteria

Exclusion criteria: Patients with schizophrenia, alcoholism, and extensive cerebrovascular disease

Design outcomes

Primary

Measure	Time frame
MMSE total scores in every 12 months.Presence or absence of a drop of 3 points or more from the baseline.	—

Secondary

Measure	Time frame
Clinical dementia rating, independence rating score in daily life of dementia, Neuropsychiatric inventory (NPI), neuropsychological assessments, hippocampal atrophy on MRI, arterial spin labeling, cerebral blood flow on SPECT, dopamine transporter imagings, amyloid PET, neuropathological findings	—

Countries

Japan

Contacts

Public ContactShinobu Kawakatsu

Aizu Medical Center, Fukushima Medical University Department of Neuropsychiatry

kshinobu@fmu.ac.jp0242-75-2100

Outcome results